Noriyuki Okudaira
Meikai University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Noriyuki Okudaira.
Anticancer Research | 2018
Haixia Shi; Junko Nagai; Tsukasa Sakatsume; Kenjiro Bandow; Noriyuki Okudaira; Yoshihiro Uesawa; Hiroshi Sakagami; Mineko Tomomura; Akito Tomomura; Koichi Takao; Yoshiaki Sugita
Background/Aim: 4H-1-Benzopyran-4-ones (chromones) provide a backbone structure for the chemical synthesis of potent anticancer drugs. In contrast to 2-(N-cyclicamino)chromones, the biological activity of 3-(N-cyclicamino)chromones has not been reported. In this study, cytotoxicity of 15 3-(N-cyclicamino)chromone derivatives was investigated and subjected to quantitative structure–activity relationship (QSAR) analysis. Materials and Methods: Cytotoxicity against four human oral squamous cell carcinoma cell lines and three oral normal mesenchymal cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Tumor-specificity (TS) was evaluated as the ratio of mean 50% cytotoxic concentration (CC50) against normal oral cells to that against human oral squamous cell carcinoma cell lines. Potency-selectivity expression (PSE) value was calculated by dividing the TS value by the CC50 against tumor cells. Apoptosis induction was evaluated by morphological observation, western blot analysis and cell-cycle analysis. For QSAR analysis, a total of 3,096 physicochemical, structural and quantum chemical features were calculated from the most stabilized structure optimized using CORINA. Results: 3-(4-phenyl-1-piperazinyl)-4H-1-benzopyran-4-one (3a) had the highest tumor specificity, comparable with that of melphalan, without induction of apoptosis. Compound 3a caused cytostatic growth inhibition and had much lower cytotoxicity against human oral keratinocytes compared to doxorubicin. TS of the 15 3-(N-cyclicamino)chromones was correlated with 3D structure and lipophilicity. Conclusion: Chemical modification of 3a may be a potential choice for designing a new type of anticancer drug.
Anticancer Research | 2018
Haixia Shi; Junko Nagai; Tsukasa Sakatsume; Kenjiro Bandow; Noriyuki Okudaira; Hiroshi Sakagami; Mineko Tomomura; Akito Tomomura; Yoshihiro Uesawa; Koichi Takao; Yoshiaki Sugita
Background/Aim: 4H-1-Benzopyran-4-ones (chromones) have provided backbone structure for the chemical synthesis of potent anticancer drugs. In this study, the cytotoxicity of fifteen 2-(N-cyclicamino)chromone derivatives was investigated and subjected to quantitative structure–activity relationship (QSAR) analysis. Materials and Methods: Cytotoxicity against four human oral squamous cell carcinoma cell lines and three oral normal mesenchymal cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Tumor specificity (TS) was evaluated by ratio of mean 50% cytotoxic concentration (CC50) against normal oral cells to that against human oral squamous cell carcinoma cell lines. Potency-selectivity expression (PSE) value was calculated by dividing the TS value by CC50 against tumor cells. Apoptosis induction was evaluated by morphological observation, western blot analysis and cell-cycle analysis. For QSAR analysis, a total of 3,089 physicochemicals, structural and quantum chemical features were calculated from the most stabilized structure optimized using Corina. Results: 7-Methoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one (5c) showed highest tumor-specificity, comparable with that of doxorubicin, without inducing apoptosis. Tumor-specificity of fifteen 2-(N-cyclicamino) chromones was correlated with molecular shape, especially 3D-structure. Conclusion: Chemical modification of 5c may be a potential choice for designing a new type of anticancer drugs.
Anticancer Research | 2018
Junko Nagai; Haixia Shi; Yuka Kubota; Kenjiro Bandow; Noriyuki Okudaira; Yoshihiro Uesawa; Hiroshi Sakagami; Mineko Tomomura; Akito Tomomura; Koichi Takao; Yoshiaki Sugita
Background/Aim: 4H-1-Benzopyran-4-one (chromone) provides a backbone structure for the chemical synthesis of potent anticancer drugs. Since studies of the biological activity of pyrano[4,3-b]chromones are limited, we investigated a total of 20 pyrano[4,3-b]chromones (10 sets of diastereomers) for their cytotoxicity against four human oral squamous cell carcinoma (OSCC) cell lines and human normal oral cells, and then carried out a quantitative structure–activity relationship (QSAR) analysis. Materials and Methods: Cytotoxicity was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method. Tumor-specificity (TS) was evaluated by the ratio of mean 50% cytotoxic concentration (CC50) against normal oral cells to that against human OSCC cell lines. Potency-selectivity expression (PSE) value was calculated by dividing the TS value by the CC50 against tumor cells. Apoptosis induction was evaluated by morphological observation, western blot analysis and cell-cycle analysis. For QSAR analysis, a total of 3,072 physicochemical, structural and quantum chemical features were calculated from the most stabilized structure optimized using CORINA. Results: 8-Chloro-4,4a-dihydro-3-methoxy-3-methyl-3H,10H-pyrano[4,3-b][1]benzopyran-10-one (16) and 3-ethoxy-4,4a-dihydro-8-methoxy-3H,10H-pyrano[4,3-b][1]benzopyran-10-one (17) had the highest TS, higher than that of 5-flurouracil and melphalan, without induction of apoptosis. Compound 16 induced cytostatic growth inhibition and much lower cytotoxicity against human normal oral keratinocytes compared to doxorubicin. TS of 20 pyrano[4,3-b]chromones was correlated with 3D structure, polarity, ionic potential and electric state. Conclusion: Chemical modification of 16 may be a potential choice for designing a new type of anticancer drug.
Medicinal Chemistry Research | 2018
Halise Inci Gul; Cem Yamali; Gulsen Gunesacar; Hiroshi Sakagami; Noriyuki Okudaira; Yoshihiro Uesawa; Hajime Kagaya
In the present study, chalcones “(E)-1-(10H-phenothiazine-2-yl)-3-aryl-prop-2-en-1-ones, FS1-11” were successfully synthesized via base-catalyzed Claisen–Schmidt condensation. Chemical structures of the compounds were confirmed by 1H NMR, 13C NMR, and HRMS techniques. Aryl part of the chalcone was changed as mono, di, and trimethoxylated phenyls. Cytotoxicities of the phenothiazine derivatives were evaluated against four human oral squamous cell carcinoma (OSCC) cell lines (Ca9-22, HSC-2, HSC-3, and HSC-4) and three human normal oral cells (HGF, HPLF, and HPC) by MTT test. The CC50 values of the compounds were calculated in the range of 0.9–109.8 µM towards OSCC malign cell lines. Trimethoxylated compound FS6, (E)-1-(10H-phenothiazine-2-yl)-3-(2,4,5-trimethoxyphenyl)-prop-2-en-1-one, was found the most selective cytotoxic compound among the series with the highest selectivity index (SI) (SI = 76.5) and potency-selectivity expression (PSE) (PSE = >1285; > 1602) values. Western blot analysis demonstrated that FS6 (8–64 μM) induced the production of cleaved product of PARP and the activation of caspase-3 in HSC-2 cells, suggesting the induction of apoptosis by FS6. QSAR analysis suggested that the tumor specificity of the chalcones correlated with their molecular shape, volume, and electrostatic properties.
in Vivo | 2016
Kunihiko Fukuchi; Noriyuki Okudaira; Kazunori Adachi; Reina Odai-Ide; Shigeru Watanabe; Hirokazu Ohno; Masaji Yamamoto; Taisei Kanamoto; Shigemi Terakubo; Hideki Nakashima; Yoshihiro Uesawa; Hajime Kagaya; Hiroshi Sakagami
in Vivo | 2016
Hiroshi Sakagami; Hong Sheng; Noriyuki Okudaira; Toshikazu Yasui; Hidetsugu Wakabayashi; Junye Jia; Takenori Natori; Madoka Suguro-Kitajima; Hiroshi Oizumi; Takaaki Oizumi
Medicinal Chemistry Research | 2017
Cem Yamali; Dilan Ozmen Ozgun; Halise Inci Gul; Hiroshi Sakagami; Cavit Kazaz; Noriyuki Okudaira
Anticancer Research | 2017
Hiroshi Sakagami; Noriyuki Okudaira; Yoshiko Masuda; Osamu Amano; Satoshi Yokose; Yumiko Kanda; Madoka Suguro; Takenori Natori; Hiroshi Oizumi; Takaaki Oizumi
in Vivo | 2016
Noriyuki Okudaira; Yukihito Ishizaka; Hajime Nishio; Hiroshi Sakagami
in Vivo | 2016
Yukiko Tomikoshi; Maki Nomura; Noriyuki Okudaira; Hiroshi Sakagami; Hidetsugu Wakabayashi